Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced/Preserved Ejection Fraction
European Journal of Heart Failure2024Vol. 26(7), pp. 1524–1538
Citations Over TimeTop 10% of 2024 papers
Mingming Yang, Toru Kondo, Atefeh Talebi, Pardeep S. Jhund, Kieran F. Docherty, Brian Claggett, Muthiah Vaduganathan, Erasmus Bachus, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Rudolf A. de Boer, Mikhail Kosiborod, Akshay S. Desai, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, John J.V. McMurray
Abstract
Both higher (better) EQ-5D-5L VAS and index scores were associated with better outcomes. Dapagliflozin treatment improved EQ-5D-5L VAS and index scores, irrespective of ejection fraction.
Related Papers
- → Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus(2011)113 cited
- → Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany(2016)4 cited
- [SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].(2013)
- → An update on dapagliflozin for chronic kidney disease(2022)1 cited
- Dapagliflozin: a selective sodium-glucose co-transporter-2 inhibitor in type 2 diabetes.(2011)